|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/22/20 Accelerated Pharma, Inc. 10-Q 9/30/19 39:1.6M M2 Compliance/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 191K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 17K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 17K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 15K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 15K
23: R1 Document and Entity Information HTML 44K
36: R2 Condensed Consolidated Balance Sheets HTML 83K
29: R3 Condensed Consolidated Balance Sheets HTML 39K
(Parenthetical)
15: R4 Condensed Consolidated Statements of Operations HTML 54K
and Comprehensive Loss (Unaudited)
24: R5 Condensed Consolidated Statements of Changes in HTML 60K
Stockholders' Deficiency (Unaudited)
37: R6 Condensed Consolidated Statements of Cash Flows HTML 72K
(Unaudited)
30: R7 Business HTML 21K
14: R8 Going Concern and Management's Liquidity Plans HTML 21K
26: R9 Significant Accounting Policies HTML 36K
19: R10 Out-of-Period Adjustment HTML 18K
17: R11 Convertible Debt HTML 21K
27: R12 Notes Payable - Related Party HTML 16K
38: R13 Stockholders' Equity HTML 18K
20: R14 Subsequent Events HTML 20K
18: R15 Significant Accounting Policies (Policies) HTML 58K
28: R16 Significant Accounting Policies (Tables) HTML 27K
39: R17 Business (Details Narrative) HTML 15K
22: R18 Going Concern and Management's Liquidity Plans HTML 27K
(Details Narrative)
16: R19 Significant Accounting Policies - Schedule of HTML 18K
Foreign Currency Translation Exchange Rate
(Details)
31: R20 Significant Accounting Policies - Schedule of HTML 25K
Potentially Dilutive Securities Excluded from
Computation of Net Loss Per Share (Details)
34: R21 Out-of-Period Adjustment (Details Narrative) HTML 38K
25: R22 Convertible Debt (Details Narrative) HTML 39K
13: R23 Notes Payable - Related Party (Details Narrative) HTML 19K
32: R24 Stockholders' Equity (Details Narrative) HTML 28K
35: R25 Subsequent Events (Details Narrative) HTML 48K
21: XML IDEA XML File -- Filing Summary XML 61K
33: EXCEL IDEA Workbook of Financial Reports XLSX 32K
6: EX-101.INS XBRL Instance -- accp-20190930 XML 379K
8: EX-101.CAL XBRL Calculations -- accp-20190930_cal XML 79K
9: EX-101.DEF XBRL Definitions -- accp-20190930_def XML 241K
10: EX-101.LAB XBRL Labels -- accp-20190930_lab XML 352K
11: EX-101.PRE XBRL Presentations -- accp-20190930_pre XML 319K
7: EX-101.SCH XBRL Schema -- accp-20190930 XSD 66K
12: ZIP XBRL Zipped Folder -- 0001493152-20-006905-xbrl Zip 47K
Exhibit 31.2
CERTIFICATION
I, Michael Fonstein, certify that:
1. I have reviewed this quarterly report of Accelerated Pharma, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report;
4. The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as 4efined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the issuer and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the issuer’s internal control over financial reporting that occurred during the issuer’s most recent fiscal quarter (the issuer’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the issuer’s internal control over financial reporting; and
5. The issuer’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer’s auditors and the audit committee of the issuer’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether not material, that involves management or other employees who have a significant role in the issuer’s internal control over financial reporting.
| Date: April 22, 2020 | |
| /s/ Michael Fonstein | |
| Principal Accounting Officer |
C:
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 4/22/20 | None on these Dates | ||
| For Period end: | 9/30/19 | |||
| List all Filings | ||||